Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicadrostat plus empagliflozin in chronic kidney disease (simultaneous vs staggered initiation)
jRCT2031250193Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vicadrostat and empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change in eGFR from baseline to Week 14. Started Jul 2025; status: recruiting.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031250193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250193.